Last reviewed · How we verify
Rhinovirus-A16 — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Rhinovirus-A16 (Rhinovirus-A16) — Imperial College London.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Rhinovirus-A16 TARGET | Rhinovirus-A16 | Imperial College London | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Rhinovirus-A16 CI watch — RSS
- Rhinovirus-A16 CI watch — Atom
- Rhinovirus-A16 CI watch — JSON
- Rhinovirus-A16 alone — RSS
Cite this brief
Drug Landscape (2026). Rhinovirus-A16 — Competitive Intelligence Brief. https://druglandscape.com/ci/rhinovirus-a16. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing